DeepMed Research

Minoxidil

Generic Name: Minoxidil

Brand Names: Loniten, Minox, Regoxidine, Rogaine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₅N_₅O

CAS Number: 38304-91-5

Unique Ingredient Identifier: 5965120SH1

Background: A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

Indication: For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.

Associated Conditions: Androgenetic Alopecia (AGA), Severe, symptomatic Hypertension

Clinical Trials

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

Phase 2

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Minoxidil

First Posted Date: 2022-03-09

Last Posted Date: 2023-10-05

Lead Sponsor: Loyola University

Target Recruit Count: 34

Registration Number: NCT05272462

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Treatment of Androgenetic Alopecia in Men for 24 Weeks

Phase 3

Completed

Conditions: Alopecia

Interventions: Drug: Minoxidil Topical Foam
Drug: Placebo

First Posted Date: 2021-01-22

Last Posted Date: 2025-02-17

Lead Sponsor: Eurofarma Laboratorios S.A.

Target Recruit Count: 336

Registration Number: NCT04721548

Locations: 🇧🇷
Eurofarma Laboratorios S.A, São Paulo, Brazil

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia

Phase 3

Recruiting

Conditions: Androgenetic Alopecia

Interventions: Drug: Finlândia Association + finasteride placebo
Drug: Minoxidil + finasteride

First Posted Date: 2020-10-20

Last Posted Date: 2024-02-16

Lead Sponsor: EMS

Target Recruit Count: 190

Registration Number: NCT04594018

Locations: 🇧🇷
Medcin Instituto Da Pele, Osasco, São Paulo, Brazil

Topical Cetirizine in Androgenetic Alopecia in Females

Phase 2

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Topical cetirizine
Drug: Placebo
Drug: Topical minoxidil

First Posted Date: 2020-07-22

Last Posted Date: 2023-02-08

Lead Sponsor: Cairo University

Target Recruit Count: 66

Registration Number: NCT04481412

Locations: 🇪🇬
Al-Kasr Al-Ainy outpatient dermatology clinic, Cairo, ِAl-Kasr Al-Ainy, Egypt

Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia

Phase 4

Conditions: Androgenetic Alopecia

Interventions: Drug: Minoxidil
Drug: Cetirizine

First Posted Date: 2020-03-03

Last Posted Date: 2020-03-04

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT04293822

Locations: 🇪🇬
Assiut University, Assiut, Egypt

N-Acetyl-Cysteine for Treatment of AGA in Men

Phase 4

Conditions: Androgenetic Alopecia

Interventions: Drug: Minoxidil 5% topically and oral NAC 600 mg

First Posted Date: 2019-12-24

Last Posted Date: 2020-02-20

Lead Sponsor: Kafrelsheikh University

Target Recruit Count: 100

Registration Number: NCT04209803

Locations: 🇪🇬
dermatology clinics in Ain Shams University Hospital and Kafr El Sheik University Hospital., Cairo, Egypt

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

Phase 4

Recruiting

Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)

Interventions: Drug: Topical steroid class I-II
Drug: Doxycyline
Drug: Triamcinolone Acetonide
Drug: Minoxidil

First Posted Date: 2019-12-23

Last Posted Date: 2025-02-04

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 250

Registration Number: NCT04207931

Locations: 🇺🇸
Wake Forest Baptist Health Department of Dermatology, Winston-Salem, North Carolina, United States

Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss

Phase 4

Completed

Conditions: Female Pattern Hair Loss

Interventions: Drug: Topical minoxidil 5% in 90% ethanol and 5% propylene glycol
Drug: Topical minoxidil 5% in pure ethanol alone
Other: Placebo (Ethanol)

First Posted Date: 2019-09-16

Last Posted Date: 2019-09-26

Lead Sponsor: Sohag University

Target Recruit Count: 60

Registration Number: NCT04090801

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

Phase 2

Withdrawn

Conditions: Male Pattern Hair Loss
Androgenetic Alopecia
Male Pattern Baldness

Interventions: Device: Laser
Drug: Post-Laser Minoxidil 2%
Drug: At-Home Minoxidil 5%
Drug: Post-laser 5mg minoxidil
Drug: Post-laser 10mg minoxidil
Drug: Post-laser 20mg minoxidil

First Posted Date: 2019-02-25

Last Posted Date: 2023-09-13

Lead Sponsor: University of Minnesota

Registration Number: NCT03852992

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Effect of Low-Dose Oral Minoxidil as Treatment of Permanent Chemotherapy-Induced Alopecia

Early Phase 1

Active, not recruiting

Conditions: Permanent Chemotherapy-induced Alopecia

Interventions: Drug: oral minoxidil

First Posted Date: 2019-02-05

Last Posted Date: 2025-04-30

Lead Sponsor: Northwestern University

Target Recruit Count: 14

Registration Number: NCT03831334

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy